Cullen Investment Group LTD. Boosts Holdings in Medtronic PLC $MDT

Cullen Investment Group LTD. increased its stake in shares of Medtronic PLC (NYSE:MDT) by 12.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 104,479 shares of the medical technology company’s stock after acquiring an additional 11,375 shares during the quarter. Medtronic comprises approximately 1.3% of Cullen Investment Group LTD.’s portfolio, making the stock its 18th largest holding. Cullen Investment Group LTD.’s holdings in Medtronic were worth $10,191,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Corundum Trust Company INC purchased a new position in shares of Medtronic during the third quarter worth about $27,000. Board of the Pension Protection Fund purchased a new stake in shares of Medtronic in the 4th quarter valued at about $29,000. GoalVest Advisory LLC purchased a new stake in shares of Medtronic in the 4th quarter valued at about $29,000. Valley Wealth Managers Inc. acquired a new stake in shares of Medtronic in the 3rd quarter valued at about $29,000. Finally, Delos Wealth Advisors LLC purchased a new position in Medtronic during the 2nd quarter worth approximately $27,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

Medtronic Trading Up 1.5%

Shares of MDT stock opened at $87.84 on Thursday. The business’s 50 day moving average is $96.22 and its two-hundred day moving average is $96.58. Medtronic PLC has a twelve month low of $79.55 and a twelve month high of $106.33. The company has a market capitalization of $112.77 billion, a P/E ratio of 24.47, a price-to-earnings-growth ratio of 2.22 and a beta of 0.71. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The business had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. During the same quarter in the prior year, the business earned $1.38 earnings per share. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts forecast that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be given a dividend of $0.71 per share. The ex-dividend date is Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a yield of 3.2%. Medtronic’s dividend payout ratio is presently 79.11%.

Analyst Ratings Changes

MDT has been the topic of several research analyst reports. UBS Group reaffirmed a “neutral” rating and set a $104.00 price target on shares of Medtronic in a research report on Wednesday, February 4th. Robert W. Baird lowered their target price on shares of Medtronic from $103.00 to $100.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 18th. Piper Sandler reaffirmed a “neutral” rating on shares of Medtronic in a report on Monday, January 5th. Wall Street Zen cut shares of Medtronic from a “buy” rating to a “hold” rating in a research note on Sunday, March 1st. Finally, Needham & Company LLC reissued a “buy” rating and set a $120.00 price objective on shares of Medtronic in a research report on Tuesday, March 10th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $110.74.

Insider Buying and Selling

In other news, EVP Harry Skip Kiil sold 52,524 shares of the firm’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the sale, the executive vice president owned 32,768 shares in the company, valued at approximately $3,201,761.28. This trade represents a 61.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.26% of the company’s stock.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Distribution deal expands Medtronic’s chronic‑pain portfolio — Medtronic agreed to distribute Merit Medical’s FDA‑cleared ViaVerte basivertebral nerve ablation (BVNA) system, adding a minimally invasive, implant‑free option for chronic vertebrogenic low‑back pain and broadening its interventional pain offering. This can support revenue growth in a high‑demand pain segment. Medtronic and Merit Medical Systems enter into agreement
• Positive Sentiment: FDA expands indication for OmniaSecure lead — The FDA cleared an expanded indication that allows placement of Medtronic’s OmniaSecure defibrillation lead in the left bundle branch area for conduction‑system pacing, strengthening its electrophysiology product lineup and supporting growth in cardiac rhythm management. Medtronic Announces FDA Approval for Expanded Indication of OmniaSecure
• Positive Sentiment: Spin‑off of diabetes unit remains a strategic catalyst — Coverage and commentary note Medtronic’s planned diabetes‑unit spin‑off later this year; separating the high‑growth diabetes business may unlock valuation for both the diabetes standalone and the remaining higher‑margin device franchises. This is a medium‑term positive for investor sentiment. Medtronic to Spin-Off High-Growth Diabetes Unit
• Neutral Sentiment: Analyst sentiment and “undervalued” mentions — Recent writeups and analyst coverage label MDT a moderate buy/undervalued blue‑chip, which can support steadier investor interest but is unlikely to trigger large moves absent fundamentals. Medtronic Given Consensus Rating of “Moderate Buy”
• Negative Sentiment: Guidance cut and charge tied to MiniMed approvals — Medtronic lowered its 2026 earnings outlook, citing a private‑equity related charge connected to MiniMed approval updates. That revision is a direct near‑term earnings headwind and a clear negative on short‑term sentiment. Medtronic cuts 2026 guidance on private equity charge related to MiniMed approval

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).